Search
Search
About
Log in
Join
Experiences with
Saphnelo
Posts
Communities
11 public posts
Filter results
Intensified Saphnelo dosing seen to benefit lupus nephritis patients
From these, 23 were on standard
Saphnelo
, 29 on intensified
Saphnelo
, and 23 on the placebo.
From these, 23 were on standard
Saphnelo
, 29 on intensified
Saphnelo
, and 23 on the placebo.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
8 months ago
Greater use of Benlysta, Saphnelo seen in US, EU to treat lupus
The results showed that, compared with 2022, the use of both Benlysta and
Saphnelo
increased by 32% in both regions.
The results showed that, compared with 2022, the use of both Benlysta and
Saphnelo
increased by 32% in both regions.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
8 months ago
Saphnelo infusion center in EU
My USA insurance says I would need to find and infusion center that offers
Saphnelo
, pay, and submit reimbursment later.
My USA insurance says I would need to find and infusion center that offers
Saphnelo
, pay, and submit reimbursment later.
Tanitatani
in
LUPUS UK
1 year ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
LFA self-management care program for lupus gets free mobile appNonprofit's new app will ease use of SELF program for patients
AstraZeneca is the developer of
Saphnelo
, an approved therapy for moderate to severe systemic lupus erythematosus, the most common form of lupus. [i]https://lupusnewstoday.com/news/lfa-lupus-self-management-care-program-gets-free-mobile-app/?
AstraZeneca is the developer of
Saphnelo
, an approved therapy for moderate to severe systemic lupus erythematosus, the most common form of lupus. [i]https://lupusnewstoday.com/news/lfa-lupus-self-management-care-program-gets-free-mobile-app/?
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
9 months ago
IFN-1 levels before treatment may be biomarker of SLE activity: Study
Saphnelo
(anifrolumab-fnia), an approved treatment for adults with moderate to severe SLE, works by blocking the receptor to which IFN-1 normally bind. Most studies supporting the association between IFN-1 activity and the features of SLE have focused on treated patients.
Saphnelo
(anifrolumab-fnia), an approved treatment for adults with moderate to severe SLE, works by blocking the receptor to which IFN-1 normally bind. Most studies supporting the association between IFN-1 activity and the features of SLE have focused on treated patients.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
1 year ago
2 New Meds Found to Completely Change Lupus Nephritis Treatment
The report noted that
Saphnelo
and Gazyva are two of the investigational therapies for lupus nephritis being viewed with particular excitement by clinicians.
https://lupusnewstoday.com/news/2-new-meds-completely-changed-lupus-nephritis-treatment-report/?
The report noted that
Saphnelo
and Gazyva are two of the investigational therapies for lupus nephritis being viewed with particular excitement by clinicians.
https://lupusnewstoday.com/news/2-new-meds-completely-changed-lupus-nephritis-treatment-report/?
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
1 year ago
A Phase 2 trial testing the effectiveness of afimetoran, Bristol-Myers Squibbs
The trial is recruiting participants at a site in Germany.Two disease-specific treatments have been approved to date for lupus: AstraZeneca’s
Saphnelo
(anifrolumab) and GlaxoSmithKline’s Benlysta (belimumab).
The trial is recruiting participants at a site in Germany.Two disease-specific treatments have been approved to date for lupus: AstraZeneca’s
Saphnelo
(anifrolumab) and GlaxoSmithKline’s Benlysta (belimumab).
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
2 years ago
[i][b]DxTerity Test to Guide SLE Therapy Now Available in All 50 US States[/b][/i]
These include, for example,
Saphnelo
(anifrolumab-fnia), a therapy developed by AstraZeneca that was approved to treat patients with moderate to severe SLE in the U.S. last year.
These include, for example,
Saphnelo
(anifrolumab-fnia), a therapy developed by AstraZeneca that was approved to treat patients with moderate to severe SLE in the U.S. last year.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
2 years ago
SAPHNELO (anifrolumab) anyone?
Did anyone try the new drug
Saphnelo
? It is from Astra Zeneca and the molecule is called anifrolumab. If yes, any results? Good or bad?
Did anyone try the new drug
Saphnelo
? It is from Astra Zeneca and the molecule is called anifrolumab. If yes, any results? Good or bad?
Tanitani
in
LUPUS UK
2 years ago
Lupus Foundation of America Celebrates FDA Approval of Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus
“Having another potential treatment option like
Saphnelo
is extremely exciting.” “The approval of
Saphnelo
is the culmination of years of clinical development,” said Susan M.
“Having another potential treatment option like
Saphnelo
is extremely exciting.” “The approval of
Saphnelo
is the culmination of years of clinical development,” said Susan M.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
3 years ago
Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)
In July 2021, the FDA approved
Saphnelo
(anifrolumab-fnia) as the second targeted therapy to treat adults with systemic lupus. It is designed to target and reduce the impact of the Type 1 Interferon Receptor, which may be important in lupus.
In July 2021, the FDA approved
Saphnelo
(anifrolumab-fnia) as the second targeted therapy to treat adults with systemic lupus. It is designed to target and reduce the impact of the Type 1 Interferon Receptor, which may be important in lupus.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
3 years ago
Filter results
Clear filters
Posted in
All communities
LUpus Patients Understanding and Support
9 results
LUPUS UK
2 results
Sort by
Most Relevant
Newest